A complementary approach to treating antibody-mediated transplant rejection.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 20588285.
- Also identified by DOI 10.1038/ki.2010.80.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Current treatment for antibody-mediated kidney transplant rejection is inadequate. Tillou and colleagues administered recombinant C1 inhibitor to block complement activation to prevent antibody-initiated injury in sensitized baboon recipients of kidney allografts. These early but encouraging results support further testing of the safety and efficacy of complement inhibition as part of a comprehensive strategy to treat this disease, both in animal models and ultimately in humans.
Medical subject headings
- Antibodies
- Complement C1 Inhibitor Protein
- Complement Inactivating Agents
- Graft Rejection
- Kidney Transplantation